Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Holding a MIRror up to the robustness of the prostate cancer urinary transcriptome.

Connor AE, Jordan AC, Perry AS.

Transl Androl Urol. 2019 Dec;8(Suppl 5):S488-S490. doi: 10.21037/tau.2019.09.25. No abstract available.

2.

Evaluating liquid biopsies for methylomic profiling of prostate cancer.

Silva R, Moran B, Russell NM, Fahey C, Vlajnic T, Manecksha RP, Finn SP, Brennan DJ, Gallagher WM, Perry AS.

Epigenetics. 2020 Jan 31:1-13. doi: 10.1080/15592294.2020.1712876. [Epub ahead of print]

PMID:
32000564
3.

Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference.

Charmsaz S, Collins DM, Perry AS, Prencipe M.

Cancers (Basel). 2019 Aug 7;11(8). pii: E1125. doi: 10.3390/cancers11081125.

4.

A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients.

Connell SP, Hanna M, McCarthy F, Hurst R, Webb M, Curley H, Walker H, Mills R, Ball RY, Sanda MG, Pellegrini KL, Patil D, Perry AS, Schalken J, Pandha H, Whitaker H, Dennis N, Stuttle C, Mills IG, Guldvik I; Movember GAP1 Urine Biomarker Consortium, Parker C, Brewer DS, Cooper CS, Clark J.

BJU Int. 2019 May 20. doi: 10.1111/bju.14811. [Epub ahead of print]

5.

epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer.

O'Reilly E, Tuzova AV, Walsh AL, Russell NM, O'Brien O, Kelly S, Dhomhnallain ON, DeBarra L, Dale CM, Brugman R, Clarke G, Schmidt O, O'Meachair S, Patil D, Pellegrini KL, Fleshner N, Garcia J, Zhao F, Finn S, Mills R, Hanna MY, Hurst R, McEvoy E, Gallagher WM, Manecksha RP, Cooper CS, Brewer DS, Bapat B, Sanda MG, Clark J, Perry AS.

JCO Precis Oncol. 2019;2019. doi: 10.1200/PO.18.00134. Epub 2019 Jan 14.

6.

A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.

Zhao F, Olkhov-Mitsel E, Kamdar S, Jeyapala R, Garcia J, Hurst R, Hanna MY, Mills R, Tuzova AV, O'Reilly E, Kelly S, Cooper C; Movember Urine Biomarker Consortium, Brewer D, Perry AS, Clark J, Fleshner N, Bapat B.

Clin Epigenetics. 2018 Nov 23;10(1):147. doi: 10.1186/s13148-018-0575-z.

7.

Transient Cell-to-Cell Signaling Before Mitosis in Cultures of Human Bone Marrow-Derived Mesenchymal Stem/Stromal Cells.

Cui J, Chen G, Perry AS, Abdi S.

Stem Cells Dev. 2019 Jan 15;28(2):120-128. doi: 10.1089/scd.2018.0165. Epub 2018 Dec 20.

PMID:
30358482
8.

Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer.

Murphy K, Murphy BT, Boyce S, Flynn L, Gilgunn S, O'Rourke CJ, Rooney C, Stöckmann H, Walsh AL, Finn S, O'Kennedy RJ, O'Leary J, Pennington SR, Perry AS, Rudd PM, Saldova R, Sheils O, Shields DC, Watson RW.

Mol Oncol. 2018 Sep;12(9):1513-1525. doi: 10.1002/1878-0261.12348. Epub 2018 Aug 7.

9.

Epigenetics of malignant melanoma.

Moran B, Silva R, Perry AS, Gallagher WM.

Semin Cancer Biol. 2018 Aug;51:80-88. doi: 10.1016/j.semcancer.2017.10.006. Epub 2017 Oct 23. Review.

PMID:
29074395
10.

Assessing DNA Methylation in Cancer Stem Cells.

Das S, Moran B, Perry AS.

Methods Mol Biol. 2018;1692:157-178. doi: 10.1007/978-1-4939-7401-6_15.

PMID:
28986896
11.

Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer.

Barrabés S, Llop E, Ferrer-Batallé M, Ramírez M, Aleixandre RN, Perry AS, de Llorens R, Peracaula R.

Clin Chim Acta. 2017 Jul;470:97-102. doi: 10.1016/j.cca.2017.05.009. Epub 2017 May 8.

PMID:
28495148
12.

Expression of the TPα and TPβ isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer: clinical significance and diagnostic potential.

Mulvaney EP, Shilling C, Eivers SB, Perry AS, Bjartell A, Kay EW, Watson RW, Kinsella BT.

Oncotarget. 2016 Nov 8;7(45):73171-73187. doi: 10.18632/oncotarget.12256.

13.

Epigenetic Methodologies for the Study of Celiac Disease.

Perry AS, Baird AM, Gray SG.

Methods Mol Biol. 2015;1326:131-58. doi: 10.1007/978-1-4939-2839-2_13.

PMID:
26498619
14.

Improving multivariable prostate cancer risk assessment using the Prostate Health Index.

Foley RW, Gorman L, Sharifi N, Murphy K, Moore H, Tuzova AV, Perry AS, Murphy TB, Lundon DJ, Watson RW.

BJU Int. 2016 Mar;117(3):409-17. doi: 10.1111/bju.13143. Epub 2015 May 24.

15.

Activity and participation in children with neurofibromatosis type 1.

Johnson BA, Sheng X, Perry AS, Stevenson DA.

Res Dev Disabil. 2015 Jan;36C:213-221. doi: 10.1016/j.ridd.2014.10.004. Epub 2014 Oct 24.

PMID:
25462482
16.

Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma.

Kusne Y, Carrera-Silva EA, Perry AS, Rushing EJ, Mandell EK, Dietrich JD, Errasti AE, Gibbs D, Berens ME, Loftus JC, Hulme C, Yang W, Lu Z, Aldape K, Sanai N, Rothlin CV, Ghosh S.

Sci Signal. 2014 Aug 12;7(338):ra75. doi: 10.1126/scisignal.2005196.

17.

Increased aPKC Expression Correlates with Prostatic Adenocarcinoma Gleason Score and Tumor Stage in the Japanese Population.

Perry AS, Furusato B, Nagle RB, Ghosh S.

Prostate Cancer. 2014;2014:481697. doi: 10.1155/2014/481697. Epub 2014 Apr 29.

18.

Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'?

Walsh AL, Tuzova AV, Bolton EM, Lynch TH, Perry AS.

Trends Mol Med. 2014 Aug;20(8):428-36. doi: 10.1016/j.molmed.2014.03.005. Epub 2014 May 13. Review.

PMID:
24836411
19.

Noncoding RNAs in prostate cancer: the long and the short of it.

Bolton EM, Tuzova AV, Walsh AL, Lynch T, Perry AS.

Clin Cancer Res. 2014 Jan 1;20(1):35-43. doi: 10.1158/1078-0432.CCR-13-1989. Epub 2013 Oct 21. Review.

20.

Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma.

Hwang DH, Szeto DP, Perry AS, Bruce JL, Sholl LM.

Arch Pathol Lab Med. 2014 May;138(5):626-35. doi: 10.5858/arpa.2013-0179-OA. Epub 2013 Jun 5.

PMID:
23738762
21.

Manipulating the epigenome for the treatment of urological malignancies.

O'Rourke CJ, Knabben V, Bolton E, Moran D, Lynch T, Hollywood D, Perry AS.

Pharmacol Ther. 2013 May;138(2):185-96. doi: 10.1016/j.pharmthera.2013.01.007. Epub 2013 Jan 24. Review.

22.

Mining methylome databases.

O'Rourke CJ, Murphy TM, Hollywood D, Perry AS.

Trends Genet. 2013 Feb;29(2):63-5. doi: 10.1016/j.tig.2012.10.015. Epub 2012 Nov 23. No abstract available.

PMID:
23182652
23.

Prostate cancer epigenomics.

Perry AS.

J Urol. 2013 Jan;189(1):10-1. doi: 10.1016/j.juro.2012.10.015. Epub 2012 Oct 12. No abstract available.

PMID:
23063895
24.

Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.

Gray SG, Baird AM, O'Kelly F, Nikolaidis G, Almgren M, Meunier A, Dockry E, Hollywood D, Ekström TJ, Perry AS, O'Byrne KJ.

Int J Mol Med. 2012 Dec;30(6):1505-11. doi: 10.3892/ijmm.2012.1138. Epub 2012 Sep 21.

PMID:
23007409
25.

Gene expression analysis in prostate cancer: the importance of the endogenous control.

Vajda A, Marignol L, Barrett C, Madden SF, Lynch TH, Hollywood D, Perry AS.

Prostate. 2013 Mar;73(4):382-90. doi: 10.1002/pros.22578. Epub 2012 Aug 27.

PMID:
22926970
26.

Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer.

Perry AS, O'Hurley G, Raheem OA, Brennan K, Wong S, O'Grady A, Kennedy AM, Marignol L, Murphy TM, Sullivan L, Barrett C, Loftus B, Thornhill J, Hewitt SM, Lawler M, Kay E, Lynch T, Hollywood D.

Int J Cancer. 2013 Apr 15;132(8):1771-80. doi: 10.1002/ijc.27798. Epub 2012 Sep 28. Erratum in: Int J Cancer. 2013 Jun 1;132(11):e163.

27.

IGFBP7 promoter methylation and gene expression analysis in prostate cancer.

Sullivan L, Murphy TM, Barrett C, Loftus B, Thornhill J, Lawler M, Hollywood D, Lynch T, Perry AS.

J Urol. 2012 Oct;188(4):1354-60. doi: 10.1016/j.juro.2012.06.002. Epub 2012 Aug 17. Erratum in: J Urol. 2012 Dec;188(6):2443.

PMID:
22906661
28.

MicroRNAs as putative mediators of treatment response in prostate cancer.

O'Kelly F, Marignol L, Meunier A, Lynch TH, Perry AS, Hollywood D.

Nat Rev Urol. 2012 May 22;9(7):397-407. doi: 10.1038/nrurol.2012.104. Review.

PMID:
22613932
29.

Promoting routine stair use: evaluating the impact of a stair prompt across buildings.

Lee KK, Perry AS, Wolf SA, Agarwal R, Rosenblum R, Fischer S, Grimshaw VE, Wener RE, Silver LD.

Am J Prev Med. 2012 Feb;42(2):136-41. doi: 10.1016/j.amepre.2011.10.005.

PMID:
22261209
30.

The role of secreted frizzled-related protein 2 expression in prostate cancer.

O'Hurley G, Perry AS, O'Grady A, Loftus B, Smyth P, O'Leary JJ, Sheils O, Fitzpatrick JM, Hewitt SM, Lawler M, Kay EW.

Histopathology. 2011 Dec;59(6):1240-8. doi: 10.1111/j.1365-2559.2011.04073.x.

PMID:
22175903
31.

Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.

Forde JC, Perry AS, Brennan K, Martin LM, Lawler MP, Lynch TH, Hollywood D, Marignol L.

Urol Oncol. 2012 Nov-Dec;30(6):912-9. doi: 10.1016/j.urolonc.2010.08.015. Epub 2010 Dec 21.

PMID:
21176881
32.

The epigenome as a therapeutic target in prostate cancer.

Perry AS, Watson RW, Lawler M, Hollywood D.

Nat Rev Urol. 2010 Dec;7(12):668-80. doi: 10.1038/nrurol.2010.185. Epub 2010 Nov 9. Review.

PMID:
21060342
33.

Localized hypermutation and associated gene losses in legume chloroplast genomes.

Magee AM, Aspinall S, Rice DW, Cusack BP, Sémon M, Perry AS, Stefanović S, Milbourne D, Barth S, Palmer JD, Gray JC, Kavanagh TA, Wolfe KH.

Genome Res. 2010 Dec;20(12):1700-10. doi: 10.1101/gr.111955.110. Epub 2010 Oct 26. Erratum in: Genome Res. 2014 Jun;24(6):1052.

34.

MAD2 downregulation in hypoxia is independent of promoter hypermethylation.

Prencipe M, McGoldrick A, Perry AS, O'Grady A, Phelan S, McGrogan B, Fitzpatrick P, Watson JA, Furlong F, Brennan DJ, Lawler M, Kay E, McCann A.

Cell Cycle. 2010 Jul 15;9(14):2856-65. Epub 2010 Jul 12.

PMID:
20676051
35.

Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression.

Teo H, Ghosh S, Luesch H, Ghosh A, Wong ET, Malik N, Orth A, de Jesus P, Perry AS, Oliver JD, Tran NL, Speiser LJ, Wong M, Saez E, Schultz P, Chanda SK, Verma IM, Tergaonkar V.

Nat Cell Biol. 2010 Aug;12(8):758-67. doi: 10.1038/ncb2080. Epub 2010 Jul 11.

PMID:
20622870
36.

In silico analysis and DHPLC screening strategy identifies novel apoptotic gene targets of aberrant promoter hypermethylation in prostate cancer.

Murphy TM, Sullivan L, Lane C, O'Connor L, Barrett C, Hollywood D, Lynch T, Lawler M, Perry AS.

Prostate. 2011 Jan 1;71(1):1-17. doi: 10.1002/pros.21212.

PMID:
20564325
37.

The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers.

Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, O'Grady A, Kay E, Dunne B, Loftus B, Watson WR, Fitzpatrick JM, Woodson K, Lehman T, Hollywood D, Lynch TH, Lawler M.

Cancer Biol Ther. 2009 Jan;8(2):118-24. Epub 2009 Feb 1.

PMID:
19106642
38.

The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer.

Murphy TM, Perry AS, Lawler M.

Endocr Relat Cancer. 2008 Mar;15(1):11-25. doi: 10.1677/ERC-07-0208. Review.

PMID:
18310272
39.

Discovery of DNA hypermethylation using a DHPLC screening strategy.

Perry AS, Liyanage H, Lawler M, Woodson K.

Epigenetics. 2007 Jan-Mar;2(1):43-9. Epub 2007 Jan 15.

PMID:
17965617
40.

In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer.

Perry AS, Loftus B, Moroose R, Lynch TH, Hollywood D, Watson RW, Woodson K, Lawler M.

Br J Cancer. 2007 May 21;96(10):1587-94. Epub 2007 Apr 24.

41.

A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies.

Bagust A, Evans M, Beale S, Home PD, Perry AS, Stewart M.

Pharmacoeconomics. 2006;24 Suppl 1:5-19. Review.

PMID:
16800159
42.

The emerging roles of DNA methylation in the clinical management of prostate cancer.

Perry AS, Foley R, Woodson K, Lawler M.

Endocr Relat Cancer. 2006 Jun;13(2):357-77. Review.

PMID:
16728568
43.

Safe method for isolation of prion protein and diagnosis of Creutzfeldt-Jakob disease.

Bastian FO, McDermott ME, Perry AS, Carver LA, Dash S, Garry RF.

J Virol Methods. 2005 Dec;130(1-2):133-9. Epub 2005 Aug 15.

PMID:
16102852
44.

Dkk-1-derived synthetic peptides and lithium chloride for the control and recovery of adult stem cells from bone marrow.

Gregory CA, Perry AS, Reyes E, Conley A, Gunn WG, Prockop DJ.

J Biol Chem. 2005 Jan 21;280(3):2309-23. Epub 2004 Oct 25.

45.

Clinical neuropharmacology of drugs of abuse: a comparison of drug-discrimination and subject-report measures.

Kelly TH, Stoops WW, Perry AS, Prendergast MA, Rush CR.

Behav Cogn Neurosci Rev. 2003 Dec;2(4):227-60. Review.

PMID:
15006288
46.

In-line fiber-optic light filter.

Perry AS, Murray GM.

Appl Spectrosc. 2003 Jun;57(6):722-3. No abstract available.

PMID:
14658708
47.

The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow.

Gregory CA, Singh H, Perry AS, Prockop DJ.

J Biol Chem. 2003 Jul 25;278(30):28067-78. Epub 2003 May 9.

48.

Evolutionary re-organisation of a large operon in adzuki bean chloroplast DNA caused by inverted repeat movement.

Perry AS, Brennan S, Murphy DJ, Kavanagh TA, Wolfe KH.

DNA Res. 2002 Oct 31;9(5):157-62.

49.
50.

Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients.

Griffin AD, Perry AS, Fleming DM.

Pharmacoeconomics. 2001;19(3):293-301.

PMID:
11303417

Supplemental Content

Loading ...
Support Center